ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07725
0,00%
Bitcoin
63.367,22
-0,82%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Vaxcyte Inc (PCVX)

  7. Vaxcyte Inc (PCVX) News

PCVX Vaxcyte Inc

65,96
1,41 (2,18%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Vaxcyte Inc PCVX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
1,41 2,18% 65,96 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
66,48 65,46 67,08 65,96 64,55
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
02.4.202422:05GLOBEVaxcyte to Present at the 23rd Annual Needham Virtual..
05.3.202403:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202403:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202403:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.3.202414:30GLOBEVaxcyte Completes Enrollment of Phase 2 Study Evaluating..
01.3.202422:02EDGAR2Form 144 - Report of proposed sale of securities
01.3.202422:00EDGAR2Form 144 - Report of proposed sale of securities
27.2.202422:58EDGAR2Form S-8 - Securities to be offered to employees in employee..
27.2.202422:02EDGAR2Form 8-K - Current report
27.2.202422:01GLOBEVaxcyte Reports Fourth Quarter and Full Year 2023 Financial..
20.2.202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202422:05GLOBEVaxcyte to Report Fourth Quarter and Full Year 2023..
05.2.202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.2.202423:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.2.202400:39GLOBEVaxcyte Announces Closing of $862.5 Million Public Offering..
01.2.202422:07EDGAR2Form 144 - Report of proposed sale of securities
01.2.202422:06EDGAR2Form 144 - Report of proposed sale of securities
01.2.202422:05GLOBEVaxcyte to Present at the Guggenheim Healthcare Talks | 6th..
31.1.202423:26EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31.1.202423:19EDGAR2Form 8-K - Current report
31.1.202405:37GLOBEVaxcyte Announces Pricing of $750 Million Public Offering
30.1.202422:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30.1.202422:01GLOBEVaxcyte Announces Commencement of Proposed Public Offering..
29.1.202414:30GLOBEVaxcyte Completes Enrollment of Phase 1/2 Study Evaluating..
16.1.202422:01GLOBEVaxcyte Appoints Whitney Jones as Chief People Officer
04.1.202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:01GLOBEVaxcyte Provides Clinical and Regulatory Progress Update on..
02.1.202422:04EDGAR2Form 144 - Report of proposed sale of securities
02.1.202422:03EDGAR2Form 144 - Report of proposed sale of securities
11.12.202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.12.202322:15EDGAR2Form 144 - Report of proposed sale of securities
05.12.202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.12.202300:35GLOBEVAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in..
01.12.202322:12EDGAR2Form 144 - Report of proposed sale of securities
29.11.202322:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.11.202322:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
28.11.202314:32EDGAR2Form 8-K - Current report
28.11.202314:30GLOBEVaxcyte Appoints Jacks Lee to Board of Directors
27.11.202322:05EDGAR2Form 8-K - Current report
27.11.202322:00GLOBEVaxcyte Exercises Option and Enters into Manufacturing..
09.11.202314:30GLOBEVaxcyte Doses First Participants in Phase 1/2 Clinical Study..
06.11.202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06.11.202322:07EDGAR2Form 8-K - Current report
06.11.202322:03GLOBEVaxcyte Reports Third Quarter 2023 Financial Results and..
03.11.202321:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.11.202321:07EDGAR2Form 144 - Report of proposed sale of securities
31.10.202321:05GLOBEVaxcyte to Present at Upcoming Investor Conferences
19.10.202315:29DJNVaxcyte Gets FDA Go-Ahead on Pneumococcal Vaccine..
19.10.202314:30GLOBEVaxcyte Announces FDA Clearance of Investigational New Drug..

Kürzlich von Ihnen besucht

NASDAQ
PCVX
Vaxcyte
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten